Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 154

Sort by

Sort Order Select

Journal Articles

Abstract 3649: Artificial intelligence accelerates shared neoantigen peptide cancer vaccine development

Genwei Zhang, Jiewen Du, Xiangrui Gao, Zhenghui Wang, Qingxia Zhang, Tongren Liu, Dong Chen, Chi Han Samson Li, Kin Tak Chan, Hong Wang, Melvin Toh, Lipeng Lai

Cancer Res (2025) 85 (8_Supplement_1): 3649.

https://doi.org/10.1158/1538-7445.AM2025-3649

Published: 21 April 2025

View articletitled, Abstract 3649: Artificial intelligence accelerates shared neoantigen peptide cancer vaccine development

Journal Articles

Abstract 3536: Synergistic effects of combined PD-L1 and B7-H3 fusion protein vaccination in a mouse model of pancreatic cancer

Kenneth Nansheng Lin, Melvin Toh, Hong Wang

Cancer Res (2025) 85 (8_Supplement_1): 3536.

https://doi.org/10.1158/1538-7445.AM2025-3536

Published: 21 April 2025

View articletitled, Abstract 3536: Synergistic effects of combined PD-L1 and B7-H3 fusion protein vaccination in a mouse model of pancreatic cancer

Journal Articles

Abstract 3538: The development of neoantigen-derived peptide vaccine driven by AI epitope design and computer assisted epitope enhancement

Chi Han Samson Li, Hong Wang, Kin Tak Chan, Genwei Zhang, Jiewen Du, Lipeng Lai, Melvin Toh

Cancer Res (2025) 85 (8_Supplement_1): 3538.

https://doi.org/10.1158/1538-7445.AM2025-3538

Published: 21 April 2025

View articletitled, Abstract 3538: The development of neoantigen-derived peptide vaccine driven by AI epitope design and computer assisted epitope enhancement

Journal Articles

Abstract 3533: Claudin 6 vaccines effectively inhibit tumor growth in a syngeneic mouse colon cancer model

Na Wang, Melvin Toh, Hong Wang

Cancer Res (2025) 85 (8_Supplement_1): 3533.

https://doi.org/10.1158/1538-7445.AM2025-3533

Published: 21 April 2025

View articletitled, Abstract 3533: Claudin 6 vaccines effectively inhibit tumor growth in a syngeneic mouse colon cancer model

Journal Articles

Abstract 5804: Pathologic responses to neoadjuvant immune checkpoint inhibitor (ICI) combinations in head and neck squamous cell carcinoma (HNSCC) associate with specific CD4⁺ helper and regulatory T cell activation states and clonal plasticity

Cancer Res (2025) 85 (8_Supplement_1): 5804.

https://doi.org/10.1158/1538-7445.AM2025-5804

Published: 21 April 2025

View articletitled, Abstract 5804: Pathologic responses to neoadjuvant immune checkpoint inhibitor (ICI) combinations in head and neck squamous cell carcinoma (HNSCC) associate with specific CD4+ helper and regulatory T cell activation states and clonal plasticity

Journal Articles

Abstract C029: PM2.5-induced drug resistance in lung cancer

Chi-Yuan Chen, Chieh-Wen Chan, Tong-Hong Wang

Cancer Res (2024) 84 (22_Supplement): C029.

https://doi.org/10.1158/1538-7445.TUMBODY-C029

Published: 17 November 2024

View articletitled, Abstract C029: PM2.5-induced drug resistance in lung cancer

Journal Articles

Abstract PO3-05-10: Efficacy and safety of eribulin plus gemcitabine in second-line or beyond for patients with HER2-negative metastatic breast cancer (MBC): A multi-center, open-label, single-arm, phase II study

PeiJian Peng, Xiao-Lu Xu, Jin-Cai Zhong, Jin-Hui Ye, Zhi-Hui Wang, Hong Wang, Hong Lin, Cai-Wen Du, Guorong Zou, Jie Ouyang, Ying-Ying Shi, Fei Xu, Geng-Sheng Yu, Yong-Kui Lu, Yong-Xia Wang, Shi-En Cui, Lu-Zhen Li

Cancer Res (2024) 84 (9_Supplement): PO3-05-10.

https://doi.org/10.1158/1538-7445.SABCS23-PO3-05-10

Published: 02 May 2024

View articletitled, Abstract PO3-05-10: Efficacy and safety of eribulin plus gemcitabine in second-line or beyond for patients with HER2-negative metastatic breast cancer (MBC): A multi-center, open-label, single-arm, phase II study

Journal Articles

Abstract PO1-29-03: Efficacy, Safety, and Immunogenicity of TQ-B211 (a Trastuzumab Biosimilar) Plus Docetaxel versus Herceptin® Plus Docetaxel for HER2-positive Metastatic Breast Cancer: a Double-blind, Randomised, Multicenter, Phase 3 Trial

Cancer Res (2024) 84 (9_Supplement): PO1-29-03.

https://doi.org/10.1158/1538-7445.SABCS23-PO1-29-03

Published: 02 May 2024

View articletitled, Abstract PO1-29-03: Efficacy, Safety, and Immunogenicity of TQ-B211 (a Trastuzumab Biosimilar) Plus Docetaxel versus Herceptin® Plus Docetaxel for HER2-positive Metastatic Breast Cancer: a Double-blind, Randomised, Multicenter, Phase 3 Trial

Journal Articles

Abstract LB135: Effects of acute psychological stress on DNA damage levels in peripheral blood mononuclear cells: An experimental study with healthy human volunteers

Dana H. Bovbjerg, John Schmitz, Kurt D. Ackerman, Scott R. Beach, Albert D. Donnenberg, Jessica Manculich, Matthew F. Muldoon, Patricia L. Opresko, Patrick M. Tarwater, Hong Wang, Frank J. Jenkins

Cancer Res (2024) 84 (7_Supplement): LB135.

https://doi.org/10.1158/1538-7445.AM2024-LB135

Published: 05 April 2024

View articletitled, Abstract LB135: Effects of acute psychological stress on DNA damage levels in peripheral blood mononuclear cells: An experimental study with healthy human volunteers

Journal Articles

Abstract 6182: Artificial intelligence (AI)-powered quantification of glypican-3 (GPC3) expression facilitates patient selection for GPC3-targeted therapy in solid tumors

Ellen Meng, Robin Meng, Ying Tong, Yuchen Li, Hong Wang, Paola Fiorentini, Elham Attieh, Qi Tang, Asma Kefsi, Serena Masciari, Giovanni Abbadessa, Cecile Combeau, Lei Tang, Benoit Pasquier, Rui Wang

Cancer Res (2024) 84 (6_Supplement): 6182.

https://doi.org/10.1158/1538-7445.AM2024-6182

Published: 22 March 2024

View articletitled, Abstract 6182: Artificial intelligence (AI)-powered quantification of glypican-3 (GPC3) expression facilitates patient selection for GPC3-targeted therapy in solid tumors

Journal Articles

The Macrophage-Associated LncRNA MALR Facilitates ILF3 Liquid–Liquid Phase Separation to Promote HIF1α Signaling in Esophageal Cancer

Jia Liu, Ze-Xian Liu, Jia-Jun Li, Zhao-Lei Zeng, Jin-Hong Wang, Xiao-Jing Luo, Chau-Wei Wong, Jia-Bo Zheng, Heng-Ying Pu, Hai-Yu Mo, Hui Sheng, Qi-Nian Wu, Hao Li, Gang Wan, Bo Li, De-shen Wang, Rui-Hua Xu, Huai-Qiang Ju

Cancer Res (2023) 83 (9): 1476–1489.

https://doi.org/10.1158/0008-5472.CAN-22-1922

Published: 02 May 2023

View articletitled, The Macrophage-Associated LncRNA MALR Facilitates ILF3 Liquid–Liquid Phase Separation to Promote HIF1α Signaling in Esophageal Cancer

Includes: Multimedia, Supplementary data

Journal Articles

Abstract CT213: Biomarker analysis from Phase 1/2 study of tusamitamab ravtansine (SAR408701) in patients with advanced non-small cell lung cancer (NSCLC)

Anas Gazzah, Joon Sang Lee, Emma Wang, Nils Ternès, Hong Wang, Eric Boitier, Aude Lartigau, Mustapha Chadjaa, Colette Dib, Gaëlle Muzard, Sandrine Valence, Anne Remaury, Cintia C. Palu, Anne-Laure Bauchet

Cancer Res (2023) 83 (8_Supplement): CT213.

https://doi.org/10.1158/1538-7445.AM2023-CT213

Published: 14 April 2023

View articletitled, Abstract CT213: Biomarker analysis from Phase 1/2 study of tusamitamab ravtansine (SAR408701) in patients with advanced non-small cell lung cancer (NSCLC)

Journal Articles

Abstract 5015: Wee1 inhibition and its synthetic lethal combination with Chk1 inhibition in mouse model of neuroendocrine prostate cancer

Yapeng Chao, Yuzhou Chen, Yu Liu, Jaclyn A. Connelly, Hong Wang, Qiming Jane Wang

Cancer Res (2023) 83 (7_Supplement): 5015.

https://doi.org/10.1158/1538-7445.AM2023-5015

Published: 04 April 2023

View articletitled, Abstract 5015: Wee1 inhibition and its synthetic lethal combination with Chk1 inhibition in mouse model of neuroendocrine prostate cancer

Journal Articles

Abstract 2155: Joint modeling of safety and peripheral mode-of-action (MoA) biomarkers to support RP2D identification in Phase 1 study of SAR444245 (SAR’245) as monotherapy (mono) or combined with pembrolizumab (pembro) in patients with advanced solid tumors

Siqing Fu, Gerald S. Falchook, Minal Barve, Meredith McKean, Tira J. Tan, Charlotte Lemech, Cheng E. Chee, Neyssa Marina, Giovanni Abbadessa, Robin Meng, Federico Rotolo, Hong Wang, Jason Deng, Wenting Wang, Rui Wang, Tarek Meniawy

Cancer Res (2023) 83 (7_Supplement): 2155.

https://doi.org/10.1158/1538-7445.AM2023-2155

Published: 04 April 2023

View articletitled, Abstract 2155: Joint modeling of safety and peripheral mode-of-action (MoA) biomarkers to support RP2D identification in Phase 1 study of SAR444245 (SAR’245) as monotherapy (mono) or combined with pembrolizumab (pembro) in patients with advanced solid tumors

Journal Articles

Abstract P4-01-43: PyrotInib in combination with Capecitabine for trasTUzumab-REsistant, HER2-positive advanced breast cancer (PICTURE): a multicenter phase 2 trial

Xichun Hu, Jun Cao, Yue’e Teng, Hui-Ping Li, Lili Zhang, Quchang Ouyang, Weimin Xie, Yueyin Pan, Zhenchuan Song, Xiaoling Ling, Xiaohong Wu, Jingwei Xu, Li Li, Liping Ren, Hong Wang, Dongxian Zhou, Jing Luo

Cancer Res (2023) 83 (5_Supplement): P4-01-43.

https://doi.org/10.1158/1538-7445.SABCS22-P4-01-43

Published: 01 March 2023

View articletitled, Abstract P4-01-43: PyrotInib in combination with Capecitabine for trasTUzumab-REsistant, HER2-positive advanced breast cancer (PICTURE): a multicenter phase 2 trial

Journal Articles

Abstract 5099: Quantification of TGFβ protein levels and digital pathology-based immune phenotyping reveal biomarkers for TGF-β blockade therapy patient selection in NSCLC

Robert Pomponio, Carrie Hendricks, Sarah Mitchell Bean, Hong Wang, Sergine Brutus, Charles Biddle-Snead, Archit Khosla, Adam Stanford-Moore, Cyrus Hedvat, Qi Tang, Roger Trullo, Brigitte Demers, Rui Wang

Cancer Res (2022) 82 (12_Supplement): 5099.

https://doi.org/10.1158/1538-7445.AM2022-5099

Published: 15 June 2022

View articletitled, Abstract 5099: Quantification of TGFβ protein levels and digital pathology-based immune phenotyping reveal biomarkers for TGF-β blockade therapy patient selection in NSCLC

Journal Articles

Abstract LB062: Efficacy of Responder-derived Fecal Microbiota Transplant (R-FMT) and Pembrolizumab in Anti-PD-1 Refractory Patients with Advanced Melanoma

Cancer Res (2021) 81 (13_Supplement): LB062.

https://doi.org/10.1158/1538-7445.AM2021-LB062

Published: 01 July 2021

View articletitled, Abstract LB062: Efficacy of Responder-derived Fecal Microbiota Transplant (R-FMT) and Pembrolizumab in Anti-PD-1 Refractory Patients with Advanced Melanoma

Journal Articles

Abstract LB227: Automated image registration and alignment facilitates assessment of change in pigmented lesions of patients at risk for melanoma

William F. Maguire, Paul H. Haley, Catherine M. Dietz, Mike Hoffelder, Clara S. Brandt, Robin Joyce, Melissa D. Wilson, Darcy Ploucha, Christopher Minnier, Cindy Sander, Hong Wang, Hassane M. Zarour, Kevin J. Mitchell, Ellen K. Hughes, John M. Kirkwood

Cancer Res (2021) 81 (13_Supplement): LB227.

https://doi.org/10.1158/1538-7445.AM2021-LB227

Published: 01 July 2021

View articletitled, Abstract LB227: Automated image registration and alignment facilitates assessment of change in pigmented lesions of patients at risk for melanoma

Journal Articles

Abstract 41: Tumor resistance to CDK4/6 inhibitors and degraders determined by the expression state of CDK6

Xuewei Wu, Xiaobao Yang, Yan Xiong, Ruitong Li, Takahiro Ito, Tamer Ahmed, Zoi Karoulia, Christos Adamopoulos, Hong Wang, Li Wang, Ling Xie, Beatrix Ueberheide, Stuart Aaronson, Xian Chen, William Sellers, Sean Buchanan, Jian Jin, Poulikos I. Poulikakos

Cancer Res (2021) 81 (13_Supplement): 41.

https://doi.org/10.1158/1538-7445.AM2021-41

Published: 01 July 2021

View articletitled, Abstract 41: Tumor resistance to CDK4/6 inhibitors and degraders determined by the expression state of CDK6

Journal Articles

Abstract 2683: Serum multiplex analysis of tertiary lymphoid structure-associated chemokines/cytokines in melanoma patients

Lilit Karapetyan, Xi Yang, Hong Wang, Cindy Sander, Arivarasan Karunamurthy, John M. Kirkwood, Walter J. Storkus

Cancer Res (2021) 81 (13_Supplement): 2683.

https://doi.org/10.1158/1538-7445.AM2021-2683

Published: 01 July 2021

View articletitled, Abstract 2683: Serum multiplex analysis of tertiary lymphoid structure-associated chemokines/cytokines in melanoma patients

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract 3649: Artificial intelligence accelerates shared neoantigen peptide cancer vaccine development

Abstract 3536: Synergistic effects of combined PD-L1 and B7-H3 fusion protein vaccination in a mouse model of pancreatic cancer

Abstract 3538: The development of neoantigen-derived peptide vaccine driven by AI epitope design and computer assisted epitope enhancement

Abstract 3533: Claudin 6 vaccines effectively inhibit tumor growth in a syngeneic mouse colon cancer model

Abstract 5804: Pathologic responses to neoadjuvant immune checkpoint inhibitor (ICI) combinations in head and neck squamous cell carcinoma (HNSCC) associate with specific CD4⁺ helper and regulatory T cell activation states and clonal plasticity

Abstract C029: PM2.5-induced drug resistance in lung cancer

Abstract PO3-05-10: Efficacy and safety of eribulin plus gemcitabine in second-line or beyond for patients with HER2-negative metastatic breast cancer (MBC): A multi-center, open-label, single-arm, phase II study

Abstract PO1-29-03: Efficacy, Safety, and Immunogenicity of TQ-B211 (a Trastuzumab Biosimilar) Plus Docetaxel versus Herceptin® Plus Docetaxel for HER2-positive Metastatic Breast Cancer: a Double-blind, Randomised, Multicenter, Phase 3 Trial

Abstract LB135: Effects of acute psychological stress on DNA damage levels in peripheral blood mononuclear cells: An experimental study with healthy human volunteers

Abstract 6182: Artificial intelligence (AI)-powered quantification of glypican-3 (GPC3) expression facilitates patient selection for GPC3-targeted therapy in solid tumors

The Macrophage-Associated LncRNA MALR Facilitates ILF3 Liquid–Liquid Phase Separation to Promote HIF1α Signaling in Esophageal Cancer

Abstract CT213: Biomarker analysis from Phase 1/2 study of tusamitamab ravtansine (SAR408701) in patients with advanced non-small cell lung cancer (NSCLC)

Abstract 5015: Wee1 inhibition and its synthetic lethal combination with Chk1 inhibition in mouse model of neuroendocrine prostate cancer

Abstract 2155: Joint modeling of safety and peripheral mode-of-action (MoA) biomarkers to support RP2D identification in Phase 1 study of SAR444245 (SAR’245) as monotherapy (mono) or combined with pembrolizumab (pembro) in patients with advanced solid tumors

Abstract P4-01-43: PyrotInib in combination with Capecitabine for trasTUzumab-REsistant, HER2-positive advanced breast cancer (PICTURE): a multicenter phase 2 trial

Abstract 5099: Quantification of TGFβ protein levels and digital pathology-based immune phenotyping reveal biomarkers for TGF-β blockade therapy patient selection in NSCLC

Abstract LB062: Efficacy of Responder-derived Fecal Microbiota Transplant (R-FMT) and Pembrolizumab in Anti-PD-1 Refractory Patients with Advanced Melanoma

Abstract LB227: Automated image registration and alignment facilitates assessment of change in pigmented lesions of patients at risk for melanoma

Abstract 41: Tumor resistance to CDK4/6 inhibitors and degraders determined by the expression state of CDK6

Abstract 2683: Serum multiplex analysis of tertiary lymphoid structure-associated chemokines/cytokines in melanoma patients

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only